This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

ISS/Risk Metrics Group And Glass Lewis Recommend VaxGen Stockholders Vote 'For' Proposed Merger With OXiGENE

SOUTH SAN FRANCISCO, Calif., Jan. 25 /PRNewswire-FirstCall/ -- VaxGen, Inc. (OTC Bulletin Board: VXGN), announced today that Institutional Shareholder Services/Risk Metrics Group (ISS) and Glass, Lewis & Co. (Glass Lewis), two leading independent proxy advisory firms, recommend that VaxGen stockholders vote "FOR" the proposed merger of VaxGen, Inc. and OXiGENE, Inc. and "FOR" the Proposal to adjourn the VaxGen special meeting, if necessary, to solicit additional proxies if there are not sufficient votes in favor of the first proposal.

(Logo:  http://www.newscom.com/cgi-bin/prnh/19991112/VAXGENLOGO)

"We are pleased that both ISS and Glass Lewis, having thoroughly evaluated the proposed merger, agree with the VaxGen and OXiGENE boards of directors in recommending that stockholders vote in favor of these proposals," said James Panek, VaxGen President.  "We believe the merger with OXiGENE, which was carefully considered and unanimously approved by the VaxGen board of directors, provides the best alternative for our stockholders."

Both ISS and Glass Lewis recommend that VaxGen stockholders vote to approve both proposals:

  • A vote FOR Proposal 1: To adopt the Agreement and Plan of Merger dated as of October 14, 2009 by and among OXiGENE, Inc., VaxGen. Inc., OXiGENE Merger Sub, Inc. and James Panek as the VaxGen stockholder representative, and the transactions contemplated thereby, including the merger;
  • A vote FOR Proposal 2: To adjourn the VaxGen special meeting, if necessary, to solicit additional proxies if there are not sufficient votes in favor of the first proposal .

In coming to their recommendation, ISS concluded that: "...the merger consideration, when taking into account the escrow shares, provides a premium to stockholders.  The company's strategic rationale appears reasonable: the merger consideration appears to offer a higher value than liquidation and the company's cash position will provide funding for OXiGENE's product candidates which are already in various clinical trial phases, offering stockholders the opportunity to participate in the future growth of the combined company." [1]

In concluding that the proposed transaction is favorable to current shareholders of VaxGen, Glass Lewis states in their report: "In addition, VaxGen shareholders will hold at least 20%, and as much as 28%, of an entity that is relatively more liquid than VaxGen..."

The VaxGen Board of Directors asks that stockholders carefully evaluate the information they have been provided, and encourages all stockholders, regardless of the number of shares they own, to vote "FOR" both proposals.

Stockholders are encouraged to vote their shares now so that their vote can be counted without delay.

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG
AAPL $132.54 0.00%
FB $80.54 0.00%
GOOG $540.11 0.00%
TSLA $247.73 0.00%
YHOO $43.48 0.00%

Markets

DOW 18,232.02 -53.72 -0.29%
S&P 500 2,126.06 -4.76 -0.22%
NASDAQ 5,089.3620 -1.4320 -0.03%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs